Effects of tamoxifen on serum lipid and apolipoprotein levels in postmenopausal patients with breast cancer |
| |
| Authors: | Manuel Morales Norberto Santana Adela Soria Alicia Mosquera José Ordovás Javier Nóvoa Pedro Betancor Pilar F Valerón Bonifacio Díaz-Chico Ricardo Chirino |
| |
| Institution: | (1) Division of Medical Oncology, Hospital Nuestra Señora de la Candelaria, Tenerife, Spain;(2) Department of Cellular and Molecular Endocrinology, University Las Palmas G.C., Spain;(3) Department of Clinical Chemistry, Hospital Insular, Las Palmas, Spain;(4) Lipid Metabolism Laboratory, USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA, USA;(5) Department of Clinical Sciences, University Las Palmas de G.C. Canary Islands, Spain;(6) Dpto. Endocrinología C. & M., Centro de Ciencias de la Salud, Universidad de Las Palmas G.C., P.O. Box 550, 35080 Las Palmas de Gran Canaria, Spain |
| |
| Abstract: | Serum lipids and apolipoprotein levels were measured in twenty postmenopausal women with primary breast cancer, before and three months after tamoxifen therapy (10 mg twice a day). Tamoxifen caused a significant reduction in total serum cholesterol (10%;P < 0.02), and in low-density lipoprotein cholesterol (17%;P < 0.01), and a significant 47 % increase in the subclass 2 of the high density lipoprotein cholesterol (P< 0.01). In addition, tamoxifen caused a 16% increase in apolipoprotein A-I, a 12% decrease in apolipoprotein B (P < 0.05), and a 37% reduction in the serum concentration of lipoprotein(a) (P< 0.01). These results show that tamoxifen brings about an important improvement in serum lipid profile. |
| |
| Keywords: | apolipoproteins breast cancer cardiovascular disease lipoproteins lipoprotein(a) tamoxifen |
| 本文献已被 SpringerLink 等数据库收录！ |
|
